Stride Bears Dig In After Earnings Miss

LRN has now cleared its October 22 earnings event and the stock's response tells the clearest story of the week: a 5.7% one-day drop following the print, leaving shares at $79.40, down 3.6% on the week and only marginally positive over the past month.

The short side went into the print with conviction, and the data since has done little to dislodge it. Short interest remains at 18.3% of the free float, up about 5% over the past month and essentially unchanged week-on-week at 0.67%. The ORTEX short score has held in a tight band around 67, pulling back slightly from the 67.2 reading flagged in last week's earnings preview but remaining well above where it was in mid-October. Bears have not rushed for the exits after the print. The lending market remains permissive: availability is ample at 375%, meaning roughly three and a half shares are available to borrow for every one already lent out. The cost to borrow has ticked up 15% over the past week to 0.55%, though it remains low in absolute terms. There is no squeeze pressure here. Options positioning has edged slightly more defensive, with the put/call ratio at 0.75, about one standard deviation above its 20-day mean of 0.70, but that is well within the year's normal range and not a signal of urgency in either direction.

The Street's reaction to the print is worth watching directly. Barrington Research moved this week, lowering its price target to $115 from $125 while keeping its Outperform rating. That action, from the analyst who has covered LRN most consistently, is a signal of recalibrated expectations rather than a change of heart. BMO Capital, carrying a neutral Market Perform, had already trimmed to $90 from $93 earlier this month. The consensus mean target now stands at $102.50, implying roughly 29% upside from current levels. That gap is wide but the valuation is not demanding: the stock trades at roughly 10x trailing earnings and around 5x EV/EBITDA, with an earnings yield that ranks in the 80th percentile of the broader universe. Bulls point to 7.5% revenue growth in the most recent quarter, strong enrollment trends, and a $625 million cash pile. Bears counter that the stock had already priced in a recovery, trading at what the bear case describes as 1.2x forward revenue before the event, leaving limited room for disappointment. The sector factor score is high at 89, but the short score rank of 9 places LRN firmly among the most heavily shorted names in its group.

One detail worth carrying from the alt data layer: Stride completed its largest Q2 buyback on record (since 2014), spending $100 million in the April quarter per EDGAR XBRL filings. That signals management confidence in the stock at levels above the current price. Separately, retail attention has spiked, with the Wikipedia views signal running at a z-score of 2.4 against the stock's own 90-day history. That reflects the attention drawn by the earnings event rather than any fundamental shift, but it is the highest attention reading in recent months. No dataset has been measured to lead Stride's reported figures, so neither signal carries predictive weight for the January print.

Among the notable holders, Dimensional Fund Advisors crossed 5% and filed a fresh 13G as recently as October 8, adding 178,000 shares in the most recent reported period. BlackRock holds 15.5% of shares outstanding, the largest single position on the register. All positions are as last disclosed and subject to the standard caveat that a holder can fall below 5% without filing again. Impactive Capital, which held around 3.1% as of June 30, added 190,000 shares in the reported period, a notable accumulation for a mid-cap name in a sector under pressure.

Nearest peers offered no cover this week. LOPE fell 1.6% on the day and gained less than 1% on the week. STRA and PRDO both finished fractionally higher over five sessions. LRN's underperformance relative to the education peer group is clear, driven by its own earnings reaction rather than sector-wide selling.

The next earnings event is scheduled for January 22, 2027, giving the market 90 days to reassess. What to watch in the interim is whether bears use the post-print weakness to add further or whether the wide gap between the current price and analyst targets draws institutional buyers back in at these levels.